Anti-tumor necrosis factor (TNF) drugs for the treatment of psoriatic arthritis: an indirect comparison meta-analysis

References

• GladmanDDAntoniCMeasePCleggDONashPPsoriatic arthritis: epidemiology, clinical features, course, and outcomeAnn Rheum Dis200564Suppl 2ii14ii1715708927
   PubMed Web of Science ®Google Scholar
• RitchlinCTKavanaughAGladmanDDTreatment recommendations for psoriatic arthritisAnn Rheum Dis20096891387139418952643
   PubMed Web of Science ®Google Scholar
• RodgersMEpsteinDBojkeLEtanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis: a systematic review and economic evaluationHealth Technol Assess20111510ixxi1329
   PubMed Web of Science ®Google Scholar
• YangHCraigDEpsteinDGolimumab for the treatment of psoriatic arthritis: a NICE single technology appraisalPharmecoeconomics2012304257270
   Web of Science ®Google Scholar
• GelmanAPrior distributions for variance parameters in hiearchical modelsBayesian Anal200613515533
   Web of Science ®Google Scholar
• LambertPCSuttonAJBurtonPRAbramsKRJonesDRHow vague is vague? A simulation study of the impact of the use of vague prior distributions in MCMC using WinBUGSStat Med200524152401242816015676
   PubMed Web of Science ®Google Scholar
• JadadARMooreRACarrollDAssessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin Trials19961711128721797
   PubMedGoogle Scholar
• MeasePJGoffeBSMetzJVanderStoepAFinckBBurgeDJEtanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trialLancet2000356922738539010972371
   PubMed Web of Science ®Google Scholar
• MeasePJKivitzAJBurchFXEtanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progressionArthritis Rheum20045072264227215248226
   PubMed Web of Science ®Google Scholar
• AntoniCEKavanaughAKirkhamBSustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)Arthritis Rheum20055241227123615818699
   PubMed Web of Science ®Google Scholar
• AntoniCEKavanaughAvan der HeijdeDTwo-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)J Rheumatol200835586987618381786
   PubMed Web of Science ®Google Scholar
• KavanaughAAntoniCEGladmanDThe Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 yearAnn Rheum Dis20066581038104316439444
   PubMed Web of Science ®Google Scholar
• BucherHCGuyattGHGriffithLEWalterSDThe results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trialsJ Clin Epidemiol19975066836919250266
   PubMed Web of Science ®Google Scholar
• GladmanDDMeasePJChoyEHRitchlinCTPerdokRJSassoEHRisk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPTArthritis Res Ther2010123R11320537151
   PubMed Web of Science ®Google Scholar
• GladmanDDMeasePJCifaldiMAPerdokRJSassoEMedichJAdalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis TrialAnn Rheum Dis200766216316817046964
   PubMed Web of Science ®Google Scholar
• GladmanDDMeasePJRitchlinCTAdalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trialArthritis Rheum200756247648817265483
   PubMed Web of Science ®Google Scholar
• MeasePJGladmanDDRitchlinCTAdalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trialArthritis Rheum200552103279328916200601
   PubMed Web of Science ®Google Scholar
• MeasePJOryPSharpJTAdalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT)Ann Rheum Dis200968570270918684743
   PubMed Web of Science ®Google Scholar
• GenoveseMCMeasePJThomsonGTSafety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapyJ Rheumatol20073451040105017444593
   PubMed Web of Science ®Google Scholar
• KavanaughAMcInnesIMeasePGolimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled studyArthritis Rheum200960497698619333944
   PubMed Web of Science ®Google Scholar
• AntoniCKruegerGGde VlamKInfliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trialAnn Rheum Dis20056481150115715677701
   PubMed Web of Science ®Google Scholar
• KavanaughAAntoniCKruegerGGInfliximab improves health related quality of life and physical function in patients with psoriatic arthritisAnn Rheum Dis200665447147716096330
   PubMed Web of Science ®Google Scholar
• KavanaughAAntoniCMeasePEffect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritisJ Rheumatol200633112254225916960923
   PubMed Web of Science ®Google Scholar
• van der HeijdeDKavanaughAGladmanDDInfliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2Arthritis Rheum20075682698270717665424
   PubMed Web of Science ®Google Scholar
• MeasePJKivitzAJBurchFXContinued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanerceptJ Rheumatol200633471272116463435
   PubMed Web of Science ®Google Scholar
• MeasePJWoolleyJMBitmanBWangBCGlobeDRSinghAMinimally important difference of Health Assessment Questionnaire in psoriatic arthritis: relating thresholds of improvement in functional ability to patient-rated importance and satisfactionJ Rheumatol201138112461246521885498
   PubMed Web of Science ®Google Scholar
• MeasePJWoolleyJMSinghATsujiWDunnMChiouCFPatient-reported outcomes in a randomized trial of etanercept in psoriatic arthritisJ Rheumatol20103761221122720395648
   PubMed Web of Science ®Google Scholar
• BaranauskaiteARaffayováHKungurovNVfor RESPOND investigatorsInfliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND studyAnn Rheum Dis201271454154821994233
   PubMed Web of Science ®Google Scholar
• KimballABBensimonAGGuerinAEfficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trialAm J Clin Dermatol2011121516221110526
   PubMed Web of Science ®Google Scholar
• MeasePGenoveseMCGladsteinGAbatacept in the treatment of patients with psoriatic arthritis: results of a six-month, multicenter, randomized, double-blind, placebo-controlled, phase II trialArthritis Rheum201163493994821128258
   PubMed Web of Science ®Google Scholar
• PrinzJCFitzgeraldOBoggsRICombination of skin, joint and quality of life outcomes with etanercept in psoriasis and psoriatic arthritis in the PRESTA trialJ Eur Acad Dermatol Venereol201125555956420840349
   PubMed Web of Science ®Google Scholar
• AsahinaANakagawaHEtohTOhtsukiMfor Adalimumab M04- 688 Study GroupAdalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: efficacy and safety results from a Phase II/III randomized controlled studyJ Dermatol201037429931020507398
   PubMed Web of Science ®Google Scholar
• AttenoMPelusoRCostaLComparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugsClin Rheumatol201029439940320066450
   PubMed Web of Science ®Google Scholar
• MeasePJSignorovitchJYuAPImpact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: a pooled analysis of randomized clinical trialsDermatology201022011719940437
   PubMed Web of Science ®Google Scholar
• SterryWOrtonneJPKirkhamBComparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trialBMJ2010340c14720124563
   PubMed Web of Science ®Google Scholar
• ToriiHNakagawaHfor Japanese Infliximab Study investigatorsInfliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo- controlled multicenter trialJ Dermatol Sci2010591404920547039
   PubMed Web of Science ®Google Scholar
• van KuijkAWGerlagDMVosKA prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissueAnn Rheum Dis20096881303130918647851
   PubMed Web of Science ®Google Scholar
• BongiornoMRPistoneGDoukakiSAricòMAdalimumab for treatment of moderate to severe psoriasis and psoriatic arthritisDermatol Ther200821Suppl 2S15S20
   Google Scholar
• BrodszkyVPentekMGulacsiLEfficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatmentScand J Rheumatol200837539940018821278
   PubMed Web of Science ®Google Scholar
• FeldmanSRGottliebABBalaMInfliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasisBr J Dermatol2008159370471018627375
   PubMed Web of Science ®Google Scholar
• KristensenLEGülfeASaxneTGeborekPEfficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group registerAnn Rheum Dis200867336436917644547
   PubMed Web of Science ®Google Scholar
• RavindranVScottDLChoyEHA systematic review and metaanalysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritisAnn Rheum Dis200867685585917827183
   PubMed Web of Science ®Google Scholar
• RevickiDWillianMKSauratJHImpact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasisBr J Dermatol2008158354955718047521
   PubMed Web of Science ®Google Scholar
• SaadAASymmonsDPNoycePRAshcroftDMRisks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trialsJ Rheumatol200835588389018381787
   PubMed Web of Science ®Google Scholar
• SpadaroACeccarelliFScrivoRValesiniGLife-table analysis of etanercept with or without methotrexate in patients with psoriatic arthritisAnn Rheum Dis200867111650165118854519
   PubMed Web of Science ®Google Scholar
• StroberBTellerCYamauchiPEffects of etanercept on C- reactive protein levels in psoriasis and psoriatic arthritisBr J Dermatol2008159232233018503600
   PubMed Web of Science ®Google Scholar
• FrankelEHStroberBECrowleyJJEtanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATECutis200779432232617500381
   PubMed Web of Science ®Google Scholar
• KimballABJacksonJMSobellJMReductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trialJ Drugs Dermatol20076329930617373192
   PubMedGoogle Scholar
• Romero-MatéAGarcía-DonosoCCórdoba-GuijarroSEfficacy and safety of etanercept in psoriasis/psoriatic arthritis: an updated reviewAm J Clin Dermatol20078314315517492843
   PubMed Web of Science ®Google Scholar
• Vander CruyssenBDe KeyserFKruithofEMielantsHVan den BoschFComparison of different outcome measures for psoriatic arthritis in patients treated with infliximab or placeboAnn Rheum Dis200766113814017178763
   PubMed Web of Science ®Google Scholar
• FransenJAntoniCMeasePJPerformance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomised controlled trials of two tumour necrosis factor inhibitorsAnn Rheum Dis200665101373137816644783
   PubMed Web of Science ®Google Scholar
• GottliebABKircikLEisenDUse of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) studyJ Dermatolog Treat200617634335217853307
   PubMed Web of Science ®Google Scholar
• RitchlinCEfficacy and safety of infliximab for the treatment of psoriatic arthritisNat Clin Pract Rheumatol20062630030116932707
   PubMedGoogle Scholar
• KvienTKHeibergLieEA Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseasesClin Exp Rheumatol2005235 Suppl 39S188S19416273806
   PubMed Web of Science ®Google Scholar
• RinaldiFProvenzanoGTerminiASpinelloMLa SetaFLong term infliximab treatment for severe psoriatic arthritis: evidence of sustained clinical and radiographic responseAnn Rheum Dis20056491375137616100346
   PubMed Web of Science ®Google Scholar